lung cancer and immuno-oncology. Through collaboration with external partners and its newly established translational cell therapy engine, Takeda plans to deliver a rich pipeline of early-stage assets in the coming years.
“Elritercept has the potential to make a meaningful difference for patients with blood cancers, one of our key areas of strategic focus,” said Teresa Bitetti, President of the Global Oncology Business Unit at Takeda. “The addition of elritercept further bo...
we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our ...
Establish new external translational partnerships as needed to advance key cell therapy and cell engager science and program initiatives as needed. Serve as a thought partner for disease area strategy initiatives to accelerate our cell therapy and cell engagers pipeline. Review and approve translational ...
− Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China − Agreement Adds Third Investigational Therapy to Takeda’s Pipeline for the Potential Treatment of Celiac ...
Our unwavering philosophy of putting patients first has guided us for over 240 years. On Founder's day, we honor our history and look towards the future.
The move aims to strengthen Takeda’s oncology pipeline. From the effective date of the agreement, the company will be responsible for all subsequent development activities. The company will pay Keros $200m upfront and potentially $1.1bn in development, approval, and sales milestones. ...
了解Takeda Pharmaceutical Co., Ltd. (Takeda Pharmaceutical Co., Ltd.)公司的药物管线,治疗领域,技术平台,以及它的2项临床试验, 5篇新闻和15篇文献,疾病领域:肿瘤,内分泌与代谢疾病,血液及淋巴系统疾病,免疫系统疾病,神经系统疾病,感染,技术平台:小分子化药,
Takeda recently announced its intention to acquire TiGenix for more than 520 million euros, which will expand its late stage gastroenterology pipeline and strengthen its presence in the U.S. market, according to a press release. The acquisition includesa stem cell therapeutic...
Takeda has built a world-class, state of the art R&D engine and has generated a diverse and dynamic pipeline of approximately 40 clinical-stage new molecular entities (NMEs) that is beginning to deliver. The company’s Wave 1 pipeline NMEs, representing potential best-in-class/firs...